IAG’S CEO is Speaking on AI in Drug Development
Novel agile methodologies driven by the principals of computer science and mathematics are proposed to revolutionise how we develop drugs, help us achieve truly personalised medicine and disrupt current healthcare practices.
Together with Joann Rhodes, Director of Science, Strategy and Operations at the MSD Discovery Innovation Centre, Dr. Olga Kubassova, CEO of IAG will be speaking at the Agile Leader’s Workshop on the subject of brining AI into drug development and decision making.
Dr. Olga Kubassova, is invited as Special Guest to Convergence of AI techniques with Drug Discovery, Development & Healthtech Workshop, London, UK, 30 Sept 2019
The workshop brings together researchers and businesses involved in the drug development process for a forum of discussion on topics including; AI in revolutionizing discovery and development, the deployment of AI for truly personalized medicines and the disruption to current healthcare practices.
About Image Analysis Group (IAG)
IAG, Image Analysis Group is a unique partner to life sciences companies. IAG leverages expertise in medical imaging and the power of Dynamika™ – our proprietary cloud-based platform, to de-risk clinical development and deliver lifesaving therapies into the hands of patients much sooner. IAG provides early drug efficacy assessments, smart patient recruitment and predictive analysis of advanced treatment manifestations, thus lowering investment risk and accelerating study outcomes. IAG bio-partnering takes a broader view on asset development bringing R&D solutions, operational breadth, radiological expertise via risk-sharing financing and partnering models.
Learn more: www.ia-grp.com
Reach out: firstname.lastname@example.org
Follow the Company: Linkedin